Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission ...

Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / February 13, 2026 / RedChip Companies will air interviews with Nexalin Technology, Inc.

Exclusive: Penny stock Nexalin advances pivotal trial aiming to tackle severe insomnia

Nexalin Technology, Inc. NXL on Tuesday announced continued advancement toward its planned pivotal clinical trial evaluating HALO Clarity for moderate to severe insomnia. Insomnia Trial Overview The ...

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Through Nexalin America, the Company’s division dedicated to U.S. government engagement, the Company participated in advocacy ...
Yahoo Finance

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

HOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today ...
The National Law Review

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) ...
Seeking Alpha

Nexalin Technology CEO Provides Letter to Shareholders

I would like to thank all of you for your tremendous support, as we look towards a very bright future in 2023 and beyond. Nexalin has built a solid foundation, grounded in strong intellectual property ...
Yahoo Finance

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today ...
The National Law Review

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET ...
manilatimes

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Mark White, Nexalin's CEO stated, "Everyone at Nexalin, including our clinical and engineering teams, is excited about this landmark trial demonstrating a reduction in blood pressure in depressed ...
Becker's Hospital Review

Nexalin goes public with $9.6M offering

Mental health neurostimulation company Nexalin is going public with a $9.6 million initial public offering. Nexalin is offering 2,315,000 shares of common stock at $4.15 per share. Nexalin will trade ...
Taiwan News

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Mark White, Nexalin’s CEO stated, “Everyone at Nexalin, including our clinical and engineering teams, is excited about this landmark trial demonstrating a reduction in blood pressure in depressed ...